SARS-CoV-2-IN-13
SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1].
Product Specifications
CAS Number
[56961-10-5]
UNSPSC
12352005
Target
SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/sars-cov-2-in-13.html
Concentration
10mM
Purity
98.53
Solubility
DMSO : ≥ 125 mg/mL
Smiles
O=C(C1=C(C=CC(Cl)=C1)O)NC2=CC(Cl)=C(C=C2)[N+]([O-])=O
Molecular Formula
C13H8Cl2N2O4
Molecular Weight
327.12
References & Citations
[1]Juang YP, et al. Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2. Eur J Med Chem. 2022 May 5;235:114295.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items